Parkinson's disease (PD) is the most common movement disorder with motor and nonmotor
signs. The current therapeutic regimen for PD is mainly symptomatic as the etio …

Involuntary movements, or dyskinesia, represent a debilitating complication of levodopa (L-
dopa) therapy for Parkinson's disease (PD). L-dopa-induced dyskinesia (LID) are ultimately …

Induced pluripotent stem cells (iPS cells) are a promising source for a cell-based therapy to
treat Parkinson's disease (PD), in which midbrain dopaminergic neurons progressively …

Animal experimentation in the Parkinson's disease (PD) field is a classic example of how the
use of animal models to study diseases can have a significant impact on human health …

Parkinson's disease (PD) is a heterogenous disease with a varying age of onset, symptoms,
and rate of progression. This heterogeneity requires the use of a variety of animal models to …

Current neuroimaging techniques have very limited abilities to directly identify and quantify
neurotransmitters from brain sections. We have developed a molecular-specific approach for …

The concept of a threshold of dopamine (DA) depletion for onset of Parkinson's disease
symptoms, although widely accepted, has, to date, not been determined experimentally in …

Environmental toxins have been implicated in the etiology of Parkinson's disease. Recent
findings of defects in the ubiquitin‐proteasome system in hereditary and sporadic forms of …

High frequency stimulation (HFS) of the subthalamic nucleus (STN) is a well-established
therapeutic approach for the treatment of late-stage Parkinson's disease. Although the …

We report that a low-calorie diet can lessen the severity of neurochemical deficits and motor
dysfunction in a primate model of Parkinson's disease. Adult male rhesus monkeys were …